查看文章

Background: Alzheimer’s disease (AD) pathology can be quantified in vivo using cerebrospinal fluid (CSF) levels of amyloid-1-42 (A1-42), total-tau (t-tau), and phosphorylated tau (p-tau181p), as well as with positron emission tomography (PET) using [11C] Pittsburgh compound-B ([11C] PIB). Studies assessing concordance between these measures, however, have provided conflicting results. Moreover, it has been proposed that [11C] PIB PET may be of greater clinical utility in terms of identifying patients with mild cognitive impairment (MCI) who will progress to the dementia phase of AD. Objective: To determine concordance and classification accuracy of CSF biomarkers and [11C] PIB PET in a cohort of patients with MCI and AD.